Cubist Cidecin review extended
Executive Summary
FDA extends June 20 priority review action date for Cubist's Cidecin (daptomycin) injection three months to Sept. 20. The extension follows reformatting of data sets, which FDA classified as a "major amendment." The company still expects to launch the product for treatment of complicated skin and skin structure infections by the end of 2003...
You may also be interested in...
Cubicin clears FDA
Cubist's Cubicin, formerly Cidecin (daptomycin for injection) is approved Sept. 12 for treatment of complicated skin and skin structure infections. An FDA "Talk Paper" notes it is the first cyclic lipopeptide antibacterial agent. Cubicin's priority action review date of June 20 had been extended three months after reformatting of data sets (1"The Pink Sheet" June 23, 2003, In Brief)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.